Products for Research Use Only

BIBF 1202-13C, d3

CAT: 0804-HY-15992S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15992S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BIBF 1202-13C, d3 is the 13C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of Nintedanib (HY-50904) which inhibits VEGFR2 kinase with an IC50 of 62 nM.
UNSPSC
12352005
Target
Isotope-Labeled Compounds; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.70
Solubility
DMSO : 1.25 mg/mL (ultrasonic; warming; adjust pH to 6.5 with 1 M HCL; heat to 60°C)
Smiles
O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN([13C]([2H])([2H])[2H])CC4)=O)C=C3)/C5=CC=CC=C5)O
Molecular Formula
C29 13CH28D3N5O4
Molecular Weight
529.61
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008 Jun 15;68 (12) :4774-82.|[3]Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41 (4) :297-311.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported